Lexology March 21, 2025
Barnes & Thornburg LLP

Highlights

The HHS-OIG released a favorable opinion regarding free drugs offered to patients in financial need for a drug manufactured by the pharmaceutical company offering the assistance

The assistance offered under the proposed arrangement did not satisfy a safe harbor to the Anti-Kickback Statute (AKS)

The agency said the proposed arrangement included factors that limited concerns under the AKS and the civil monetary penalty laws

The U.S. Department of Health and Human Services’ Office of Inspector General (HHS-OIG) recently released OIG Advisory Opinion 25-01, a favorable opinion regarding the federal Anti-Kickback Statute (AKS) and civil monetary penalty laws (CMP) against beneficiary inducements as applied to a financial assistance program that would provide an intravenous drug at no cost or with...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Govt Agencies, HHS, OIG, Pharma, Pharma / Biotech
Putting infection control to the test
HHS OIG Finds Favorably for Free Access to Pharmaceutical Product
FDA’s Recent Guidance on Accelerated Approval and Implications for Rare Diseases
Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023
Medicare Part D spending on weight loss drugs surges 364%: OIG

Share This Article